Loading patent…
AssigneesThe United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of Illinois
InventorsMichael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
Estimating the term…
The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
An antihepatitis B composition which comprises a pharmaceutically acceptable carrier and an antihepatitis B effective amount of at least one compound selected from the group consisting of calanolide A, dihydrocalanolide A, calanolide B, dihydrocalanolide B, costatolide, dihydrocostatolide, soulattrolide, and dihydrosoulattrolide.
A method of preventing or treating a hepatitis B viral infection, which method comprises administering to a human an antihepatitis B effective amount of at least one compound selected from the group consisting of:
Dependencies are inferred from the claim text.